On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has been accepted by the FDA with Priority Review designation for the treatment of Type III Gaucher Disease (GD3).

The FDA acceptance was primarily based on positive results from the Phase III LEAP2MONO study. If approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3, expanding Sanofi's portfolio for lysosomal storage disease patients. The FDA's target action date is set for November 25. Additionally, Sanofi has advanced a JAK/ROCK dual-target inhibitor into clinical application, further broadening its innovative pipeline in hematology and transplantation, which collectively bolstered market sentiment.

Within the Pharmacy sector where Sanofi belongs, the overall sector showed modest gains. Among individual stocks, Eli Lilly up 1.27%, Johnson & Johnson up 0.97%, Merck up 0.78%, Bristol-Myers Squibb up 0.60%, Pfizer up 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)